030sek
2,1 %
Date:2024-10-09Time:10:51:41Latest report:Q2-2024List:First NorthTicker:LPGO
Market Cap:44 msekEnterprise Value:24 msekNet Sales:9,33 msekEarnings:-20,3 msekEmployees:0ISIN:SE0015382072

Ratios

10-year key figure history for Lipigon Pharmaceuticals turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Lipigon Pharmaceuticals with index and moving average MA50 and MA200.

Stockprice:0,30
MA50:0,29
MA200:0,34
Price/MA200:-14,0 %
RSI (14):59,7
Price/MA50:2,3 %

Description

Lipigon develops drugs for diseases caused by disorders in the body's management of fats, where adequate treatment is currently lacking or limited and where there is a great medical need. The Company initially focuses on unusual diseases that may give orphan drug status or niche indications, but in the long term the Company has the opportunity to target broader indications. The vision is to become the leading player globally in this area and be the obvious partner for major pharmaceutical companies. At the time of the Prospectus, Lipigon has four drug projects.

Pharmaceuticals